By Stine Jacobsen and Maggie Fick

COPENHAGEN (Reuters) -Novo Nordisk plans to examine in clinical trials whether its future weight-loss drugs can treat a wide range of health conditions linked to obesity, as it has already begun doing with its blockbuster drug Wegovy.

The Danish drugmaker aims to build evidence across both severe and more common obesity-related conditions that affect patients’ daily lives, such as knee osteoarthritis and sleep apnea, Martin Holst Lange, head of research and development at Novo Nordisk, told Reuters in an interview in connection with the European Association for the Study of Diabetes conference in Vienna.

“We do know that obesity is actually related to more than 200 different comorbidities,” Lange said.

Novo has not disclosed which conditions it plans t

See Full Page